No Data
No Data
Immuron's Global Sales Climb 51% in March Quarter; Shares Surge 18%
Immuron (ASX:IMC) saw a 51% surge in global sales in the March quarter compared with the prior comparative period, driven by a strong performance of its Travelan product in Australia, according to a W
ADRs Close Lower, Immuron Ltd. Declines 17.1%
This article was automatically generated by Dow Jones Newswires using technology from Automated Insights. International stocks trading in New York closed lower on Monday, as the S&P/BNY Mellon index
We're Not Very Worried About Immuron's (ASX:IMC) Cash Burn Rate
Immuron Shares Soar Premarket on Positive Travelan Study
By Colin Kellaher U.S.-listed shares of Immuron more than doubled in premarket trading Thursday after the biopharmaceutical company reported positive results from a Phase 2 study of its Travelan prod
Immuron Moving Anti-Diarrhea Drug to Phase Three Trials
Immuron (ASX:IMC) confirmed the efficacy of its single-dose Travelan drug in preventing moderate to severe diarrhea induced by Escherichia coli (E. coli) bacteria, the company said in a Wednesday fili
Immuron's Travelan Immune Supplement Registers AU$2.7 Million Sales in YTD January
Immuron (ASX:IMC) said sales of its Travelan immune supplement reached AU$2.7 million in the year to date ending January, a Tuesday filing said. Sales of the over-the-counter immune supplement for pat
No Data